August 2026 - Poly(ADP-Ribose) Polymerase Inhibitors drug patent information, global generic entry, market access

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ZEJULA	niraparib tosylate	TABLET;ORAL	214876-002	Apr 26, 2023		RX	Yes	No	8,071,579	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline	ZEJULA	niraparib tosylate	TABLET;ORAL	214876-001	Apr 26, 2023		RX	Yes	No	8,071,579	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline	ZEJULA	niraparib tosylate	TABLET;ORAL	214876-003	Apr 26, 2023		RX	Yes	Yes	8,071,579	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline	ZEJULA	niraparib tosylate	TABLET;ORAL	214876-002	Apr 26, 2023		RX	Yes	No	11,673,877	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 20, 2026

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Dynamics and Patent Landscape (2026): Exclusivity, Orange Book Risk, and Generic/Biosimilar Entry

Executive summary: PARP inhibitors drive a concentrated patent estate shaped by (1) early pioneer compound patents, (2) later-generation maintenance and combination method-of-use claims, and (3) formulation/process patents tied to tablet/solution manufacturing. Market dynamics are dominated by competition across indication-specific submarkets (ovarian, breast, prostate, pancreatic) and by payor restrictions that steer use to biomarker-selected cohorts (BRCA1/2, HRD, and platinum-sensitivity status). Generic entry risk is highest where compound protection and key method-of-use exclusivities expire and where Orange Book-listed patents are susceptible to Paragraph IV challenges; litigation outcomes often determine entry timing more than regulatory readiness. A staggered exclusivity wall is still present across the class through the early-to-mid 2030s for multiple marketed products, with patent thickets that require clearance of both active ingredient and later-life patents (dosage, polymorph/crystal form, coatings, stability, and combination regimens).

How do PARP inhibitors perform in the market by mechanism-of-action and indication?

PARP inhibitors inhibit PARP1 and PARP2, reducing base-excision repair and synthetic lethality in tumors with defective homologous recombination repair (HRR), especially BRCA1/2 alterations. Commercial traction is strongest when prescribing aligns with clinical benefit in biomarker-defined populations and after chemotherapy maintenance settings became standard-of-care in ovarian and related disease states.

What drives demand for PARP inhibitors: biomarker stratification and maintenance positioning

Commercial drivers in PARP inhibitor therapy include:

Platinum-sensitive ovarian cancer maintenance settings (with HRD/BRCA stratification).
Post-chemotherapy maintenance paradigms in ovarian and, in some regions, expanded indications via label updates.
HRR biomarker enrichment (BRCA mutations and HRD status) that concentrates response rates.
Combination strategies (with anti-angiogenics and/or immuno-oncology agents) that broaden the addressable population beyond monotherapy cohorts.

How does PARP inhibitor competition differ across ovarian, breast, prostate, and pancreatic?

Ovarian cancer: Highest density of line-of-therapy competition. Maintenance and biomarker-defined subgroups create complex switching behavior among branded options and later generic penetration.
Breast cancer: Less crowded than ovarian in early lines but still subject to payer criteria tied to BRCA mutations and HRD.
Prostate cancer: Trophy biomarker dynamics (BRCA and other HRR genes) and stronger emphasis on prior treatment sequencing, shaping adoption and persistence.
Pancreatic cancer: Smaller base but meaningful label-driven use when biomarker and prior-therapy criteria align.

Key market dynamic: patent cliffs are indication-specific

Even when an active ingredient loses core compound protection, remaining exclusivity can persist via:

Method-of-use claims for specific combinations or maintenance sequences.
Dosing regimen patents (intermittent vs continuous; starting dose modifications; dose interruption rules).
Formulation or process patents that do not block all generics but can restrict certain dosage forms or manufacturing workarounds.

What patents protect PARP inhibitors: compound, method-of-use, and formulation/process claims?

PARP inhibitor IP estates typically stack three layers: pioneer molecule composition, downstream life-cycle improvements, and regimen/formulation protection.

What composition-of-matter patents cover PARP inhibitor active ingredients

Class-defining composition-of-matter (CoM) families generally protect:

Specific small-molecule structures (core scaffold).
Substituted analogs with defined chemical classes.
Salt forms where a claim set is structured to control commercial drug substance variants.

What method-of-use patents cover PARP inhibitor treatment regimens

Regimen claims commonly protect:

Monotherapy maintenance and post-platinum outcomes.
Combination regimens with chemotherapy and/or targeted agents (often anti-angiogenic combinations).
Tumor biomarker-stratified uses (HRD, BRCA mutation, and specific HRR gene categories), depending on how the claim language is drafted.

What formulation and manufacturing patents cover PARP inhibitor tablets and dosing

Formulation and process portfolios often protect:

Tablet composition and coating layers (including dissolution and bioavailability control).
Polymorph/crystal form, solvates, and hydrates.
Stability and shelf-life-related processing windows.
Manufacturing process steps and impurity controls that constrain generic replication.

How strong is the patent estate for PARP inhibitors in practice

“Strength” typically correlates with:

Number of Orange Book-listed patents per NDA (or per listed dosage form).
Claim coverage breadth across active ingredient, formulation, and key methods of use.
Litigation history including PTAB challenges and district court outcomes.
Settlement patterns that establish de facto entry dates even when filings suggest earlier launch.

When do PARP inhibitors lose exclusivity: compound patent expiration vs regulatory exclusivity?

PARP exclusivity calendars differ by product and geography. For US-specific timing, “exclusivity” is often a mix of:

Patent term for CoM and downstream patents.
FDA regulatory exclusivity (New Chemical Entity, New Molecular Entity, pediatric exclusivity, and use-related exclusivities where applicable).
Orange Book-listed patent expirations tied to formulation and method-of-use claims.

How to read class-level timing: why entry often waits for the last listed patent

Generic launch readiness is constrained by:

The latest expiring Orange Book patent with a basis for a Paragraph IV notice.
Injunction and settlement agreements following Paragraph IV litigation.

Why exclusivity outcomes differ across PARP inhibitors

Even within the same MoA class, products can show different:

Patent term adjustments (PTA) granted by FDA during regulatory review.
Downstream continuation filings that extend method-of-use or formulation coverage.
Settlement-driven “carve-out” schedules where generic entry starts for some indications before others.

What is the Orange Book status of PARP inhibitor products, and how many patents typically block generic entry?

Orange Book status is product-specific. In class practice, the Orange Book listing density is driven by:

Multiple dosage forms (tablets at multiple strengths).
Broad formulation patent families that are separately listed per strength.
Multiple method-of-use patents that each cover distinct regimens.

How many Orange Book patents matter for Paragraph IV risk

For generic entry, the key variable is not the total number of Orange Book patents, but:

Whether the ANDA applicant can design around formulation claims.
Whether the ANDA filing includes a Paragraph IV challenge to patents that are most likely to be enforced (CoM or core method-of-use).
Whether the NDA sponsor has a litigation track record with fast-track injunction outcomes.

How “Orange Book listings” translate into real launch timing

Even after the regulatory pathway is secured, launch can be blocked by:

30-month stay pending litigation resolution.
Permanent injunctions or early settlements.

Which companies are challenging PARP inhibitor patents with Paragraph IV ANDAs?

Paragraph IV activity clusters among large ANDA manufacturers and specialty generics with portfolios aligned to oncology chronic therapies.

What settlement structures are common in PARP inhibitor cases

Settlement patterns often include:

Delayed entry effective dates that align with the sponsor’s last enforceable patent.
Indication carve-outs (limited launch to non-infringing label areas).
Ongoing litigation dismissal conditioned on launch triggers.

How does Paragraph IV litigation affect PARP inhibitor competition?

Where a settlement or injunction is reached:

Market share transfers often accelerate for remaining branded options until generic entry.
Payors may tighten criteria for branded products in anticipation of price erosion, shifting prescribing patterns earlier than the effective generic launch date.

What patent litigation affects PARP inhibitors: key districts, common claim targets, and typical outcomes?

PARP inhibitor litigation typically targets:

Core compound coverage (less often dispositive alone, more often the anchor for the entire estate).
Method-of-use patents aligned with the most commercial indications.
Formulation or manufacturing patents that can be harder for generics to design around.

What outcomes most commonly decide launch

District court claim construction and infringement rulings.
PTAB outcomes on invalidity theories if the sponsor pursues or the challenger leverages post-grant review pathways.
Settlement outcomes that convert litigation leverage into schedule-based entry.

How litigation outcomes change commercial assumptions

Even if a generic “wins” on a particular patent, broader outcomes can still limit launch because:

Other Orange Book patents remain enforceable.
Indication-specific patents can still block the label.

How do PARP inhibitors compare on patent depth and lifecycle strategy: olaparib, niraparib, rucaparib, talazoparib?

Class comparisons map to lifecycle choices made by each innovator around maintenance, combination therapy, and formulation control.

Olaparib: typical lifecycle approach

Broad method-of-use targeting maintenance and combination strategies.
Formulation and dosing-related claims across tablet strengths.
HRD/biomarker-aligned claims that map to label evolution.

Niraparib: typical lifecycle approach

Method-of-use coverage concentrated on maintenance settings.
Combination regimens that can extend portfolio protection into later years.
Formulation and manufacturing improvements often used to strengthen non-infringement responses.

Rucaparib: typical lifecycle approach

Targeted regimen protection for tumor- and prior-therapy-specific niches.
Downstream improvements focused on product-specific dosage strengths and stability windows.
Patent estates that often remain indication-relevant despite compound expiry.

Talazoparib: typical lifecycle approach

Dense method-of-use claims where maintenance and patient-selection criteria are central.
Formulation/process protections linked to tablet performance parameters.
Patent follow-on filings designed to track label expansion.

What formulations are protected by PARP inhibitor patent estates: tablets, salts, polymorphs, and stability?

Formulation patents can be as commercially material as compound patents because ANDA applicants often need:

Bioequivalence at specific strengths.
Stability and impurity profile compliance.
Dissolution profile matching.

What kinds of formulation claims appear most often

Tablet composition: excipients, ratios, coating layers.
Solid-state form claims: polymorphs, solvates, hydrates, crystal modifications.
Process constraints: steps that define impurity thresholds and yield.
Stability claims: shelf-life and accelerated stability testing frameworks.

How formulation patents affect generic development

Generics frequently pursue:

Alternate solid forms that do not infringe composition claims.
Manufacturing route changes to avoid protected process steps.
Bioequivalence studies calibrated to dissolution criteria rather than mere active ingredient sameness.

How do biosimilar risks apply to PARP inhibitors compared with biologics?

PARP inhibitors are small molecules; biosimilar pathways are not applicable. Competitive threats come from:

Generics under ANDA.
Authorized generics (where license structures exist).
Novel formulations or fixed-dose combinations that attempt to sidestep IP constraints through design changes.

What generic entry risks exist for PARP inhibitors: launch scenarios by patent wall location?

Scenario A: ANDA filed after core compound expiry but before method-of-use expiry

Entry is often delayed by remaining method-of-use patents.
Carve-out labeling may be required, reducing commercial upside initially.

Scenario B: ANDA filed with Paragraph IV on core CoM but formulation patents remain

Even if core compound patents fall, formulation and stability/purity patents can keep launch blocked.
Generics may still launch at a later date but not across all strengths or dosage forms.

Scenario C: ANDA filed with Paragraph IV on method-of-use patents

If district court rules narrow infringement, generic might launch with restricted indications.
If courts uphold regimen claims, sponsor settlement/injunction can extend branded market control.

Scenario D: Settlement establishes “scheduled” generic entry

Litigation may not fully resolve all patent questions, but settlement schedules become binding commercial facts.
Payors often coordinate with expected launch timing for step-down formularies.

Which licensing deals shape PARP inhibitor competition and IP access?

Lifecycle and combination licensing can be decisive in oncology because:

Combination regimens require rights to multiple assets and can create bundled market access.
Sponsor companies may license biomarkers or companion diagnostics commercially even when the underlying drug IP remains unchanged.

In PARP inhibitors, the most material licensing patterns tend to relate to:

Co-development or regional commercialization of specific formulations.
Rights to combination assets that pair PARP inhibition with other mechanisms.

How do PARP inhibitor IP barriers affect combination strategies and fixed-dose or new delivery systems?

Combination and new delivery system development face IP layering because:

Method-of-use claims can cover the combination and the sequence (maintenance after platinum, concomitant dosing).
Formulation patents can cover co-formulation stability windows.
Process patents may constrain outsourcing partners.

As a result, developers often rely on:

Distinct dosing schedules that can be argued as non-infringing.
New formulation forms that avoid protected solid-state variants.
New active ingredient salts or excipient matrices that change composition claim coverage.

Key Takeaways

PARP inhibitors operate under stacked IP: compound, method-of-use, and formulation/process. Commercial risk for generics tracks the last enforceable Orange Book-listed patent tied to the most monetized indication.
Market dynamics remain indication- and biomarker-specific, with payors tightening criteria that affect adoption curves and persistence.
Paragraph IV litigation and settlements often determine the real launch date more than FDA readiness.
Formulation and manufacturing patents can delay or restrict launch even after core compound protection ends.
Biosimilar risk is not applicable; competitive threats are ANDA-led generic entry and, selectively, authorized generics or combination-level arrangements.

FAQs

1) What is the typical number of Orange Book patents listed for PARP inhibitor NDA dosage forms?
Orange Book listing density is product- and strength-specific and is driven by CoM plus multiple downstream formulation and method-of-use families.

2) Do PARP inhibitor method-of-use patents block generic entry even after compound patents expire?
Yes. If method-of-use patents remain listed and enforceable for the relevant indication, they can block or restrict label launch.

3) Can an ANDA avoid infringement by changing the solid-state form or tablet composition?
Often, but the design-around must avoid solid-state/formulation claim scope and still meet bioequivalence and impurity specifications.

4) How do 30-month stays alter the timing of generic PARP inhibitor launches?
A Paragraph IV-triggered 30-month stay commonly delays market entry until litigation resolves or settlement sets an earlier or later effective date.

5) Are combination regimens with PARP inhibitors more IP-sensitive than monotherapy?
Often. Combination method-of-use claims can be drafted narrowly yet still map to high-revenue labeled regimens, increasing infringement and settlement leverage.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. Paragraph IV Certifications and Related Information. U.S. Food and Drug Administration. https://www.fda.gov/
FDA. Exclusivity Determinations for Drugs. U.S. Food and Drug Administration. https://www.fda.gov/drugs/development-approval-process-drugs/
United States Patent and Trademark Office (USPTO). Patent Trial and Appeal Board (PTAB) rules and procedures. https://www.uspto.gov/boards/bp/bpai/ptab